Ethnic minority groups less informed about cancer symptoms
the ONA take:
According to new findings presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, United Kingdom, ethnic minorities in England were less informed about cancer symptoms and were less likely to see a doctor when they thought they had a possibly serious symptom.
Researchers at King's College London in London, United Kingdom, analyzed about 50,000 responses from the Cancer Research UK Cancer Awareness Measure, a national population-based survey to investigate levels of cancer awareness. Researchers found that people with a black ethnic background were half as likely as white people to identify unexplained bleeding as a possible cancer symptom.
People of South Asian descent were a one-fourth as likely as white people to identify an explained lump as a possible cancer symptom. In addition, people with South Asian backgrounds were more likely to report embarrassment and low confidence to discuss their symptoms with their doctor, while white people were more concerned about wasting the physician's time.
The findings suggest that more public awareness is needed to help people identify cancer symptoms earlier in disease progression and that people need to be encouraged to discuss unexplained changes in their body with their physician.
Ethnic minorities less informed about cancer symptoms and less likely to see a doctor.
Ethnic minorities in England are less aware of cancer symptoms and more likely to say they wouldn't see the doctor, even when they have a symptom that they think might be serious, according to research being presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
Researchers looked at nearly 50,000 responses to the Cancer Research UK Cancer Awareness Measure* from people across England. They found that ethnic minority groups were consistently less aware of cancer symptoms.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Patients and Caregivers Worry About Cost of Cancer Care
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- How to Help Patients at the End of Life and Their Loved Ones During the Holidays
- Real-World Prevalence of AEs With Immune Checkpoint Inhibitors for NSCLC Higher Than Reported in Trials
- Disparities Seen in Goals-of-Care Discussions With Minority vs Nonminority Patients
- Acupuncture Eases Some Self-Reported Symptoms of Cancer, Cancer Treatments
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|